Literature DB >> 27349268

Implications of FoxP3-positive and -negative CD4(+) CD25(+) T cells in Graves' ophthalmopathy.

Kazuhiko Matsuzawa1, Shoichiro Izawa, Tsuyoshi Okura, Shinya Fujii, Kazuhisa Matsumoto, Kyoko Shoji, Risa Nakamura, Keisuke Sumi, Yohei Fujioka, Akio Yoshida, Chiaki Shigemasa, Masahiko Kato, Kazuhiro Yamamoto, Shin-Ichi Taniguchi.   

Abstract

Graves' ophthalmopathy (GO) is a common manifestation of Graves' disease (GD); however, its pathogenesis is not well understood. Recently, the dysregulation of regulatory T cells (Tregs) has been thought to be closely associated with the pathogenesis and clinical symptoms of autoimmune disease. We therefore evaluated whether T cell subsets, including Tregs, are associated with GO pathogenesis and clinical symptoms. In this observational study we evaluated 35 GD patients with overt ophthalmopathy (GOs) and 28 patients without ophthalmopathy (non-GOs). Fifteen healthy euthyroid patients served as healthy controls (HCs). Peripheral blood mononuclear cells from GOs, non-GOs and HCs were analyzed for CD4, CD25, and FoxP3 expression using flow cytometry. We also evaluated their correlation with disease activity according to the clinical activity score (CAS) and magnetic resonance imaging (MRI) findings. Disease severity was evaluated using the NOSPECS score, and clinical progression of GO was followed for 24 weeks. The main outcome measures were the frequencies of FoxP3-positive and -negative CD4(+) CD25(+) T cells at study outset, namely Tregs and effector T cells (Teffs), respectively. GOs had higher frequencies of Teffs (30.8±8.4%) than non-GOs (19.4±7.1%) and HCs (22.7±7.9%). Notably, patients with improved GOs had lower frequencies of Tregs (5.8±1.1%) than patients with stable or deteriorated GOs (7.3±1.2%), although ophthalmic and radiological parameters were not significantly different at the start of the study. In conclusion, an expanded Teff population may be associated with GO pathogenesis. Additionally, decreased Tregs in peripheral blood may predict a good clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27349268     DOI: 10.1507/endocrj.EJ16-0108

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.

Authors:  M Siomkajło; Ł Mizera; D Szymczak; K Kolačkov; J Grzegrzółka; M Bolanowski; J Daroszewski
Journal:  J Endocrinol Invest       Date:  2021-04-17       Impact factor: 4.256

2.  Decreased Expression of TIM-3 on Th17 Cells Associated with Ophthalmopathy in Patients with Graves' Disease.

Authors:  J Zhao; B Lin; H Deng; X Zhi; Y Li; Y Liu; P W Bible; Q Li; B Xu; L Wei; H Yang; D Huang
Journal:  Curr Mol Med       Date:  2018       Impact factor: 2.222

3.  Immunological Features of Paranasal Sinus Mucosa in Patients with Graves' Orbitopathy.

Authors:  Yi Lu; Yu Wu; Yazhuo Huang; Sijie Fang; Yinwei Li; Jing Sun; Huifang Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-10       Impact factor: 5.555

Review 4.  Research progress on the pathogenesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes.

Authors:  Jingyi Zheng; Honghong Duan; Sufang You; Bo Liang; Yuping Chen; Huibin Huang
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.